0 255

Cited 25 times in

Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus

Authors
 Hae Jin Kim  ;  Soo Kyung Kim  ;  Wan Sub Shim  ;  Jae Hyuk Lee  ;  Kyu Yeon Hur  ;  Eun Seok Kang  ;  Chul Woo Ahn  ;  Sung Kil Lim  ;  Hyun Chul Lee  ;  Bong Soo Cha 
Citation
 DIABETES RESEARCH AND CLINICAL PRACTICE, Vol.81(1) : 42-49, 2008 
Journal Title
 DIABETES RESEARCH AND CLINICAL PRACTICE 
ISSN
 0168-8227 
Issue Date
2008
MeSH
Adult ; Blood Glucose/metabolism ; Blood Pressure ; Body Mass Index ; Diabetes Mellitus, Type 2/blood* ; Diabetes Mellitus, Type 2/drug therapy* ; Diabetes Mellitus, Type 2/physiopathology ; Female ; Glycated Hemoglobin A/metabolism ; Humans ; Hypoglycemic Agents/therapeutic use* ; Insulin/blood ; Insulin/physiology ; Leptin/blood* ; Male ; Middle Aged ; Thiazolidinediones/therapeutic use* ; Waist-Hip Ratio
Keywords
Rosiglitazone ; Leptin ; Insulin sensitivity ; Subcutaneous adiposity
Abstract
Rosiglitazone (RSG) is known to be an agonist for the peroxisome proliferator-activated receptor-gamma (PPARgamma) and promotes differentiation of pre-adipocytes into adipocytes. Leptin is highly correlated with adiposity, while the activation of PPARgamma is known to inhibit Lep gene expression and leptin release. This study was performed to evaluate the relationship between changes in circulating leptin levels, insulin sensitivity and regional adiposity after RSG treatment. Two hundred fifty-one type 2 diabetic patients (176 men and 75 women) who had been treated with sulfonylurea and/or metformin received 4 mg of RSG daily, in addition to the previous medications. Before and after RSG treatment (average duration 5.6+/-0.9 months), indices of insulin resistance, metabolic parameters, and serum leptin and adiponectin levels were measured. Abdominal subcutaneous fat thickness (SFT(max)) and visceral fat thickness were measured by sonography. After RSG treatment, HOMA-IR index decreased significantly (2.82+/-1.94 vs. 2.01+/-1.58), while BMI and SFT(max) increased, and leptin (4.72+/-3.77 vs. 5.69+/-4.30 ng/ml) and adiponectin levels (7.54+/-10.20 vs. 12.89+/-10.13 microg/ml) increased. The increase in serum leptin correlated with an increase in SFT(max) (r=0.511, p<0.001) and with a reduction in HOMA-IR (r=-0.368, p<0.001). The correlation of Delta leptin with Delta HOMA-IR and with Delta SFT(max) was higher in females and among insulin-resistant subjects. In conclusion, RSG improves the insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus, which is related to an increase in subcutaneous adiposity.
Full Text
http://www.sciencedirect.com/science/article/pii/S016882270800082X
DOI
10.1016/j.diabres.2008.02.001
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Eun Seok(강은석) ORCID logo https://orcid.org/0000-0002-0364-4675
Ahn, Chul Woo(안철우) ORCID logo https://orcid.org/0000-0003-3733-7486
Lee, Jae Hyuk(이재혁)
Lee, Hyun Chul(이현철)
Lim, Sung Kil(임승길)
Cha, Bong Soo(차봉수) ORCID logo https://orcid.org/0000-0003-0542-2854
Hur, Kyu Yeon(허규연)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/106730
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse